Compare DexCom, Inc. (DXCM) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Petróleo Brasileiro SA — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while Petróleo Brasileiro SA trades at $17.71 (market cap $108.05B). The key difference: Petróleo Brasileiro SA is far larger — about 3.9× DexCom, Inc.'s market cap, and Petróleo Brasileiro SA pays a 9.87% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PBR | |
|---|---|---|
Market Cap | $28.06B | $108.05B |
Sector | Health | Technology |
52-Week High | $89.53 | $22.03 |
52-Week Low | $54.84 | $11.54 |
Enterprise Value | $27.03B | $170.59B |
Dividend Yield | — | 9.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Petrobras (PBR) trades at $17.78, down 0.78% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 5.69, net income margin of 21.47%, and robust cash flow generation of $197.51B from operations in 2025. Recent developments include strategic acquisitions in Africa and renewable energy investments, while Q1 2026 earnings missed expectations but Q3 and Q4 2025 results beat estimates.
PBR presents compelling value with attractive valuation metrics and strong profitability, supported by analyst consensus of $23.90 price target (34% upside). Key risks include oil price volatility and regulatory pressures in Brazil. The company's dividend payments and strategic expansion into renewable fuels provide additional investor appeal amid ongoing operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
